Background: The aim of the present study was to investigate relationships between the risk of chronic kidney disease (CKD) and obesity and weight changes in Asian patients with type 2 diabetes. Methods: At baseline (2003-05), 1187 diabetic patients aged 30-70 years were recruited to the study, with follow-up surveys completed in 2008, 2009, and 2010. Chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min per 1.73 m 2 ; body mass index (BMI) was categorised as normal (18.5-22.9 kg/m 2 ), overweight (23-27.4 kg/m 2 ), or obese (≥27.5 kg/ m 2 ); waist circumference (WC) ≥80 cm for women and ≥90 cm for men was taken to indicate abdominal obesity. Changes in weight and WC were calculated from baseline to each follow-up survey. Relative risk (RR) and 95% confidence intervals (CIs) of CKD were estimated. To estimate the risk for incident CKD, associations were examined in patients without CKD at baseline (n = 881). Results: Over 7 years of follow-up, obesity (RR 1.48; 95% CI 1.08-2.04; P = 0.015) and high WC (RR 1.23; 95% CI 1.00-1.52; P = 0.049) were associated with CKD after adjusting for covariates. Among participants without CKD at baseline, those who gained >10% weight (RR 1.43; 95% CI 1.07-1.90; P = 0.015) and in whom WC increased >15% (RR 1.37; 95% CI 1.01-1.85; P = 0.045) had a higher risk of incident CKD than those who remained stable (AE5% changes in weight or WC). Conclusions: Diabetic patients who are obese and those with excessive central fat were more likely to have CKD. Large weight gain (>10%) and increases in WC (>15%) independently predicted incident CKD.
Introduction
Obesity is a major risk factor for type 2 diabetes mellitus (T2DM), hypertension, and other comorbid conditions. 1 People with T2DM in both middle-aged and elderly populations face an increased risk of chronic kidney disease (CKD) and end-stage renal disease (ESRD). 2 In Taiwan, diabetes is the primary leading cause of ESRD, accounting for over 40% of new cases of ESRD. 3 Taiwan has a higher prevalence of obesity than other Asian countries. 4 Although obesity is less prevalent in Asian populations than that in Caucasians, Asians are relatively more susceptible to chronic health conditions than Caucasians with lower levels of body mass index (BMI) and waist circumference (WC). 5, 6 A meta-analysis suggested that both overweight and obesity increase the risk of kidney disease in the general population; however, the association between BMI and kidney disease in patients with hypertension or other kidney-related conditions is a mix of positive, null, and U-shaped associations. 7 In contrast, a few studies have found higher BMI to be a protective factor for CKD, ESRD, or renal function deterioration in patients with T2DM and nephropathy. [8] [9] [10] An important and less clear question is whether changes in body weight and abdominal circumference in patients with chronic conditions, such as diabetes, affect the development of CKD. Observational studies of healthy men have found weight gain to increase the risk of CKD, 11, 12 even when baseline BMI remains within the normal range. 11 A significant U-shaped association between weight change and the risk of CKD has been observed after adjusting for baseline BMI. 11 Waist increase was also found to be associated with the development of CKD in the general population. 13 To the best of our knowledge, no studies have examined the effects of changes in weight and WC on the risk of developing CKD in patients with T2DM in the Asian population.
Most previous studies that examined obesity-related diseases used BMI measures at a single time, which may not provide the best estimates over time within one person, particularly among people with T2DM. The weight of these people may range from normal to obese or may fluctuate over time if they are not careful in following treatment recommendations. A repeatedmeasures design can provide a more definitive evaluation of within-person changes across time and increase statistical power. 14 Thus, the present study used obesity and renal data obtained from four surveys (baseline and three follow-up surveys) administered to a Taiwanese population with T2DM to examine obesity (BMI and WC) in relation to the risk of having CKD. Participants with CKD at baseline were then excluded and the data obtained from the three subsequent surveys was used to investigate whether baseline obesity parameters and changes in weight and WC predict new-onset CKD. Among these CKD-free participants, relationships between changes in weight or WC and changes in estimated glomerular filtration rate (eGFR) were also examined. We hypothesized that obesity and weight gain would increase the risk of CKD and that weight gain would be associated with a greater rate of eGFR decline.
Methods

Study participants
Study participants were patients with T2DM, aged 30-70 years, who had participated in the Diabetes Management through an Integrated Delivery System (DMIDS) project in Taiwan. 15 Subjects were recruited from 36 clinics located in northern, middle, and southern Taiwan. Details of the study design and selection criteria for the original cohort have been published previously. 15 Briefly, 1209 participants who had no major diabetic complications (e.g. dialysis or foot amputations) or other systemic illnesses (e.g. myocardial infarction, stroke, or cancer) were recruited at baseline (2003-05) and were followed up in 2008, 2009, and 2010 . Participants who did not have complete BMI and serum creatinine at baseline (n = 10) and those who were classified as underweight based on BMI <18.5 kg/ m 2 (n = 12) were excluded, leaving 1187 subjects for analysis. Underweight participants were excluded because of the possibility of malnutrition or unintentional weight loss.
To examine the effects of baseline obesity and changes in body weight and WC on the risk of developing CKD, participants with CKD at baseline (n = 64) were excluded. Of the remaining participants, 242 did not return or had incomplete data on the variables of interest in at least one follow-up survey, leaving 881 CKD-free participants at baseline for the longitudinal analyses. The protocol of the present study was approved by the ethics committees of the National Health Research Institutes and Kaohsiung Medical University Hospital, Taiwan. All participants provided written informed consent.
Assessment of obesity and changes in body weight and WC
Body mass index and WC were measured at baseline and in three subsequent surveys. Body weight (in light clothes and no shoes) was measured to the nearest 0.1 kg on standardized digital weight scales. Height without shoes was measured to the nearest 0.5 cm on standardized, wall-mounted height boards. Body mass index was constructed as a consecutive term and as a categorical variable (normal weight 18.5-22.9 kg/m 2 , overweight 23-27.4 kg/m 2 , and obese ≥27.5 kg/m 2 ) using the World Health Organization (WHO) cut-off points of 23 and 27.5 kg/m 2 for disease risk among Asian populations. 5 In addition, Asian cut-off points were used to define normal WC (<80 cm for women, <90 cm for men) and abdominal obesity (WC ≥80 for women, ≥90 for men). 6 The group with abdominal obesity was further categorised into high WC (80-87 cm for women, 90-101 cm for men) and very high WC (≥88 for women, ≥102 for men).
Relative changes in body weight and WC were calculated from baseline to each follow-up survey. For example, the relative weight change between baseline and 2010 was calculated as (2010 weight -baseline weight)/ baseline weight × 100%, and was categorised as weight loss >10%, weight loss >5%-10%, stable weight (AE5%), weight gain >5%-10%, and weight gain >10%. 12, 16 Changes in WC were calculated using similar methods and categorized as WC decrease >10%, WC decrease >5%-10%, stable WC (AE5%), WC increase >5%-10%, WC increase >10%-15%, and WC increase >15%.
Assessment of CKD
Serum creatinine was measured by the Jaffe reaction at each survey. Estimated GFR was assessed using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation with a four-level race variable (Black, Asian, Hispanic and Native American, or White and other). 17 Chronic kidney disease was defined as an eGFR <60 mL/min per 1.73 m 2 . 18 Annual changes in eGFR from baseline to each follow-up survey were calculated (as mL/min per 1.73 m 2 per year).
Assessment of covariates
Age, gender, duration of diabetes, and education level (≤6 or >6 years) were recorded at baseline. Socioeconomic status information was only collected at a follow-up survey and categorized as low, medium, or high. Diabetic retinopathy was diagnosed with a detailed eye examination performed by qualified and trained ophthalmologists at baseline. At baseline and each follow-up survey, data on smoking status (never, past, current smoker) and alcohol consumption (at least once a week during the previous 6 months) were collected by simple questions in the questionnaires. Three blood pressure measures were taken, and average blood pressure was calculated. Hypertension was defined as blood pressure ≥140/ 90 mmHg or self-reported of use of antihypertensive medications (yes, no); HbA1c was assessed using HPLC (G7; Tosoh, Kobe, Japan). Fasting (≥8 h) triglycerides and cholesterol were assessed using an autoanalyzer (LX20; Beckman Coulter, Fullerton, CA, USA). Urinary creatinine was measured by the Jaffe reaction method, and urinary albumin was measured by immunoturbidimetry (Hitachi High Technologies, Tokyo, Japan). Albuminuria was defined as a urinary albumin: creatinine ratio (ACR) ≥30 mg/g. 18 Data on physical activity (getting exercise within the past 2 weeks) and energy intake were only assessed in the follow-up surveys and not at baseline. A 45-item food frequency questionnaire was used to evaluate the usual frequency of consumption (using a six-point scale ranging from almost never to ≥1 time per day) and the serving size of food items over the previous 12 months. For each participant, dietitians calculated daily energy intake (kcal/ day) based on the average serving size of foods consumed per day.
Statistical analysis
Pearson Chi-squared tests and analyses of variance (ANOVA) were used to compare baseline demographic and clinical characteristics among the three BMI categories. General linear models were used to estimate adjusted eGFR among the obesity (BMI and WC) categories in each survey, and trajectories of adjusted eGFR across time were plotted as line graphs.
Generalized estimating equation (GEE) models, which account for variations within a person between repeated surveys and handle missing values, were used to examine the cross-sectional association between obesity (BMI and WC) and the risk of CKD. Log-Poisson distribution (log-binomial distribution did not converge) was used to estimate relative risks (RR) and their 95% confidence intervals (95% CIs), and the exchangeable structure was used for the working correlation matrix. Time was included as a covariate in all models. Ageadjusted RRs were estimated before adjusting for diabetes duration, gender, education, smoking status (never, past, current smoker), and alcohol consumption (yes, no) in Model 1. To examine whether the risks were independent of the main risk factors for diabetic complications, we further adjusted for HbA1c, triglycerides, blood pressure, and the use of antihypertensive medication (yes, no) in Model 2. Age, diabetes duration, smoking status, alcohol consumption, HbA1c, triglycerides, blood pressure, and medication use were considered as time-varying covariates. Socioeconomic status was highly correlated with education and did not affect the association between obesity and CKD, thus we did not include this variable in the adjusted model. Exercise (yes, no) and energy intake (kcal/day) were also considered as covariates, and data from the 2008, 2009, and 2010 surveys revealed that they did not change the association. Because the data on exercise and energy intake were not available at baseline, the models did not include these two covariates.
The GEE models were also used to examine the longitudinal associations of baseline obesity (BMI and WC) and changes in weight and WC with the risk of incident CKD in patients without CKD at baseline (n = 881). The models were adjusted for the baseline covariates mentioned above. Patients with diabetic retinopathy and albuminuria may be prone to developing kidney disease; thus, the models were additionally adjusted for baseline retinopathy and albuminuria (ACR ≥30 mg/g) in Model 3. The models for weight change and WC change were also adjusted for BMI and WC at baseline, respectively. The interactions between baseline BMI and weight change, as well as between baseline WC and WC change, were tested. Among the CKD-free participants, the relationship between changes in weight or WC and changes in eGFR were examined using data from the three repeated measures. Because the relationship did not differ by time, repeated-measures data were aggregated in the GEE models adjusted for time, age, diabetes duration, gender, and baseline BMI (or WC). Two-sided P < 0.05 was considered significant. All statistical analyses were performed using SPSS version 22.0 (IBM Corp. Armonk, NY, USA).
Results
Baseline characteristics of study participants
Of 1187 participants with T2DM (48% men), 64 had CKD at baseline. These patients had a mean age of 55.8 years, with mean diabetes duration of 5.0 years, mean BMI 26.0 kg/m 2 , mean WC 88.0 cm, mean HbA1C 69 mmol/mol, and mean eGFR 98.9 mL/min per 1.73 m 2 at baseline. Participants who were excluded because of non-return or incomplete data (n = 242) were older, had a lower level of education, had poorer glycemic control and kidney function, and were more likely to have a lower BMI than those who were included in the analyses. Baseline characteristics of the study participants stratified by BMI categories are given in Table 1 . At baseline, half the participants were overweight (BMI 23-27.4 kg/m 2 ) and 30% were obese (BMI ≥27.5 kg/m 2 ) when applying Asian BMI cut-off points; nearly twothirds (61.4%) were abdominally obese. In this population, there were more overweight men, but more obese women (P = 0.003). Compared with the normal weight group (BMI 18.5-22.9 kg/m 2 ), those in the obese group tended to be younger (54.1 vs 56.3 years) and had a shorter duration of diabetes (4.0 vs 6.5 years). As expected, WC, blood pressures, and triglycerides increased and eGFR decreased with increasing BMI. However, the obese group had lower HbA1C (67 vs 75 mmol/mol), lower antihypertensive medication use (41.9% vs 66.7%), and a lower prevalence of diabetic retinopathy (19.2% vs 31.6%) than the normal weight group. These lower values may be explained by a significantly shorter duration of diabetes or the younger age of the obese group. No significant differences were found in urinary ACR among the three groups.
Cross-sectional associations between obesity and CKD Levels of adjusted eGFR according to BMI and WC categories defined at baseline and in each follow-up survey are shown in Figs 1 and 2. After adjustment for age, diabetes duration, and gender, participants with obese BMI and obese WC had significantly lower levels of eGFR across the 7-year study period compared with those with normal BMI and WC (P < 0.05 in all surveys).
The prevalence of CKD was 5.4% at baseline and increased to 15.4% in the 2010 survey. The associations between BMI, WC, and risk of CKD using repeated measures are given in Table 2 . In the GEE models, ageadjusted RRs for CKD were 1.21 (95% CI 0.93-1.59) for the overweight category and 1.46 (1.07-2.00) for the obese category compared with the normal weight category. In addition, abdominal obesity was associated with an increased risk of CKD (RR 1.22; 95% CI 1.00-1.49). The association of obesity (RR 1.48; 95% CI 1.08-2.04; P = 0.015) and abdominal obesity (RR 1.23; 95% CI 1.00-1.52; P = 0.049) with CKD remained statistically significant after further adjustment for HbA1c, triglycerides, and hypertension (Model 2). These positive associations were also observed when BMI and WC were expressed as continuous variables.
Longitudinal associations between obesity, weight changes, and incident CKD Among CKD-free participants, approximately 40% had a weight change greater than AE5%. Participants who gained weight (>5%) had a significant increase in their WC compared with those whose body weight remained within AE5% of baseline values (+5.0 vs +1.2 cm, respectively; P < 0.001).
In the multivariable GEE model (Model 2), after adjustment for baseline BMI, HbA1c, triglycerides, and hypertension, weight gain >10% was significantly associated with an increased risk of developing CKD (RR 1.43; 95% CI 1.07-1.90; P = 0.015) compared with stable weight (AE5%; Table 3 ). In addition, a large WC increase (>15%) was significantly associated with an increased risk of incident CKD (RR 1.37; 95% CI 1.01-1.85; P = 0.045) compared with stable WC (AE5%). Further adjustment for baseline retinopathy and albuminuria did not alter the associations (Model 3). The risk estimates of large weight gain >10% remained unchanged (RR 1.45; 95% CI 1.07-1.97; P = 0.016). Retinopathy (RR 1.62; 95% CI 1.13-2.32; P = 0.009) and albuminuria (ACR ≥30 mg/g; RR 2.46; 95% CI P-values for continuous variables were examined using analysis of variance (ANOVA), whereas the Chi-squared test was used for categorical variables. ‡ Information regarding socioeconomic status was only collected from the follow-up survey (n = 787). § Albuminuria was defined as a urinary albumin : creatinine ratio (ACR) ≥30 mg/g. DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
1.73-3.50; P < 0.001) were both significant risk factors for the development of CKD. However, baseline BMI and WC did not appear to be associated with the risk of incident CKD. In addition, there was no significant interaction between baseline BMI and weight change in relation to the risk of developing CKD. baseline BMI (Fig. 3) . Participants who gained >10% weight had a larger rate of eGFR decline compared with those whose weight remained stable (AE5%; −0.53 mL/ min per 1.73 m 2 per year; 95% CI −1.17, 0.11; P = 0.105), although the annual rate of decline did not reach statistical significance. Similar relationships were observed between changes in WC and changes in eGFR.
Weight changes and eGFR changes
Discussion
In the present longitudinal study of Taiwanese patients with T2DM, participants who were obese (BMI ≥27.5 kg/m 2 ) and with an excessive WC (≥80 cm for women and ≥90 cm for men) were more likely to have CKD than those with a normal BMI and WC, respectively. However, among the CKD-free participants, baseline BMI and WC did not predict new-onset CKD over the study period. It should be noted that in this diabetic population the obese group was younger and had a short duration of diabetes than the normal weight group at baseline. The risk of incident CKD was 1.4-fold greater for CKD-free participants who gained >10% of their baseline body weight and a similar risk effect was found for those in whom WC increased >15% of baseline compared with those whose weight and WC remained stable (AE5%), respectively. The risks were independent of hyperglycemia, dyslipidemia, hypertension, diabetic retinopathy, and albuminuria. Furthermore, weight gain was found to be associated with a greater decline in eGFR.
To our knowledge, the associations between obesity and kidney disease have not been investigated extensively in the diabetic population, and the results thus far are mixed. One of study found that high WC but low BMI independently predicted new-onset CKD over a follow-up period of 5 years in Chinese patients with T2DM, although low BMI may reflect muscle wasting and lipolysis as a result of hyperglycemia and insufficient insulin action. 9 Keane et al. 8 also reported that low BMI was a significant predictor of developing ESRD over a 3.4-year follow-up period in patients with T2DM and nephropathy; however, that effect disappeared in multivariable analysis. One Taiwanese longitudinal study found that high BMI reduced the risk of renal function decline in T2DM patients with an advanced stage of CKD (Stages 3 or 4). 10 However, Mohsen et al. 19 reported that high BMI did not effect the rate of progression to CKD in T2DM, even when patients were at the end stage of CKD. 19 These conflicting results may be the consequence of patients at different stages of CKD, different kidney outcomes over different lengths of follow-up, and adjustment for various confounders.
In line with the findings of the present study, results from two prospective studies of healthy men showed that men with a weight gain >10% (vs stable weight AE5%) 12 or a weight gain ≥0.75 kg/year (vs stable weight −0.25 to <0.25 kg/year) 11 had an increased risk of Data are presented as the relative risk (RR) and 95% confidence intervals (CI). *Generalized estimating equation (GEE) models were performed using repeated measures data from baseline, 2008, 2009 and 2010 surveys. Each participant had a maximum of four observations. Model 1 was additionally adjusted for diabetes duration, gender, education (≤6, >6 years), smoking status (never, past, current smoker), and drinking habit (yes, no). Model 2 contained all the covariates in Model 1 plus HbA1C, triglycerides, and hypertension (high blood pressure or antihypertensive medication use).
incident CKD. One large-scale long-term study, with a median follow-up duration of 9 years, also found that severe waist gain ≥9 cm (vs stable waist AE2 cm) adversely affected the incidence of CKD in men. 13 However, the exact cause of the gain in weight and WC is unclear in diabetic patients. Insulin therapy commonly results in weight gain, which can adversely affect cardiovascular risk factors. 20 In the present study, only 11 participants were receiving insulin injections at baseline, and there was no detailed information on the use of medications that stimulate insulin production. Future studies need to further explore the role of insulinstimulating medications in the link between weight gain and diabetes-related kidney disease.
The American Diabetes Association (ADA) 21 and the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) 22 clinical guidelines recommend that overweight and obese individuals (BMI ≥25 kg/m 2 ) with diabetes lose 10% of their body weight to improve risk factors. Meta-analyses of intervention studies have shown the beneficial effects of weight loss >5% on HbA1C, lipids, and blood pressure in overweight and obese adults with T2DM. 23 Very few observational studies support the long-term benefits of weight loss on the development of CKD in T2DM.
Although in the present study participants who lost 5%-10% of their baseline body weight had the lowest rate of eGFR decline (Fig. 3) , we did not find a significantly reduced risk of developing CKD in this group. Data are presented as the relative risk (RR) with 95% confidence intervals (CI) in parentheses. *Participants with chronic kidney disease (CKD) at baseline were excluded. Generalized estimating equation (GEE) models were performed using repeated measures data from the 2008, 2009 and 2010 surveys. Each participant had a maximum of three observations. † All RRs (95% CI) for the association between weight change and incident CKD were adjusted for baseline body mass index (continuous), and RRs (95% CI) for the association between waist change and incident CKD were adjusted for baseline waist circumference (continuous). Model 1 was additionally adjusted for diabetes duration, gender, education (≤6, >6 years), smoking status (never, past, current smoker), and drinking habit (yes, no) at baseline. Model 2 was adjusted for all covariates in Model 1 plus HbA1c, triglycerides, and hypertension (high blood pressure or antihypertensive medication use) at baseline. Model 3 was adjusted for all covariates in Model 2 plus diabetic retinopathy and albuminuria at baseline.
Recently, the Look AHEAD (Action for Health in Diabetes) study performed an intensive lifestyle intervention (reduced caloric consumption and increased physical activity) for overweight and obese adults with T2DM. 16, 24 One of these studies found that modest weight loss of 5%-10% at 1 year was associated with significant improvements in blood pressure, glycemic status, and lipid profile. 16 After an 8-year follow-up, the incidence of very high-risk CKD was lower in the intervention group, suggesting a long-term beneficial effect of weight loss interventions on the development of diabetic kidney disease. 24 Based on the current (limited) evidence, whether improvements in clinical risk factors such as blood pressure and blood sugar after weight loss translate to an attenuated risk of CKD or delay the rate of progression of CKD in patients with diabetes is yet to be fully determined.
Pro-inflammatory interleukin (IL)-6 may explain, in part, the pathogenic mechanisms by which weight gain is associated with the risk of developing CKD in T2DM. In a supplementary analysis, we examined the relationship between weight gain, IL-6, and CKD using plasma samples collected in 2008. The CKD-free patients who gained weight over time had significantly increased concentrations of IL-6 compared with those whose weight remained stable (P = 0.002; see Fig. S1 ). Concentrations of IL-6 were inversely correlated with eGFR levels and positively associated with CKD using data from the 2008 survey (see Table S1 ). In a previous prospective study, we also found that IL-6 was an independent predictor of eGFR decline in T2DM. 25 Studies of both human and animal subjects have reported that IL-6 is a key cytokine functioning downstream of angiotensin II and that it contributes to upregulating the expression of prepro-endothelin-1 and profibrotic genes, subsequently leading to hypertension and kidney fibrosis. 26 Obesity and diabetes both promote lowgrade inflammation and macrophage infiltration into the kidneys. 27 The infiltrated macrophages increase the release of the pro-inflammatory marker IL-6, both locally within adipose tissue and systemically. 27, 28 One weight loss trial reported a significant improvement in IL-6, and this improvement remained at 24 months, regardless of weight regain. 29 Therefore, IL-6, in its role as a pro-inflammatory mediator, may be one of the possible mechanisms underlying the link between weight gain and diabetes-related nephropathy.
The present study has several unique strengths. To our knowledge, the present study is the first to examine the effect of weight changes on new-onset CKD and changes in eGFR in the Asian diabetic population. The longitudinal data provided the opportunity to account for within-person fluctuations in body weight and WC and to increase statistical power. A number of limitations should be considered when interpreting the findings. First, although we adjusted for a broad range of confounding factors, lifestyle covariates (e.g. smoking status, alcohol consumption, and physical activity) were only crudely measured and lack details regarding quantity; in addition, the scales used for recording physical activity and energy intake were not validated. Residual confounding, such as unmeasured factors and medication treatments, remain a possible alternative explanation for our results. Second, participants who were excluded because of the nonreturn of surveys were older, less healthy, and had a lower BMI than those who were included in the analysis, which may have underestimated the occurrence of weight change and CKD risk. However, we cannot be sure whether this affected the observed associations. Third, we could not identify participants with unintentional weight loss and exclude them from analyses. Unintentional weight loss in elderly and sick participants can be difficult to evaluate because many nondietary and non-exercise factors are involved (e.g. side effects of medications, psychiatric disorders, loss of appetite). 30 In the present study, we could only exclude underweight participants from the analyses. Fourth, we found that there was no significant interaction between baseline BMI and weight change in relation to incident CKD, but the sample size and power may not be sufficient to enable this conclusion to be made because only a small number of participants (n < 10) were obese at baseline and gained >10% weight.
In conclusion, the findings of the present study suggest that diabetic patients who are obese based on their BMI and have excessive abdominal fat are more likely to have CKD. Large weight gain (>10%) and increases in WC >15% independently predicted new-onset CKD, and there was a significant relationship between weight gain and a greater decline in eGFR. These results provide clinical evidence that clinicians need to inform at-risk Asian patients of the effect of obesity using a lower BMI and WC, and to communicate the effect of weight gain on renal function decline more effectively to their diabetic patients. Larger, long-term prospective studies are needed to investigate the effects of insulin treatment on the association between weight gain and the development of CKD, and to study the effects of obesity and weight changes on the risk of ESRD or mortality in Asian patients with diabetes and advanced-stage CKD.
